InstitutionMD Anderson
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2024 Apr 03. PMID: 38570701.
      Citations:    Fields:    
    2. Fiskus W, Piel J, Collins MP, Hentemann M, Cuglievan B, Mill CP, Birdwell C, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver NG, Sasaki K, Takahashi K, Hammond D, Reville PK, Wang J, Loghavi S, Sen R, Ruan X, Su X, Flores L, DiNardo CD, Bhalla KN. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor. Blood. 2024 Feb 16. PMID: 38437498.
      Citations:    Fields:    
    3. Mill CP, Fiskus WC, DiNardo CD, Reville P, Davis JA, Birdwell CE, Das K, Hou H, Takahashi K, Flores L, Ruan X, Su X, Loghavi S, Khoury JD, Bhalla KN. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer J. 2024 02 05; 14(1):25. PMID: 38316746; PMCID: PMC10844204.
      Citations:    Fields:    Translation:HumansAnimalsCells
    4. Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, DiNardo CD, Pemmaraju N, Borthakur G, Davis JA, Das K, Sharma S, Horrigan S, Ruan X, Su X, Khoury JD, Kantarjian H, Bhalla KN. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 Mar; 38(3):545-556. PMID: 38086946.
      Citations:    Fields:    Translation:HumansAnimals
    5. Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360. PMID: 37585491.
      Citations:    Fields:    Translation:Humans
    6. Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica. 2023 10 01; 108(10):2626-2638. PMID: 37078252; PMCID: PMC10542840.
      Citations:    Fields:    Translation:HumansCells
    7. Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023 Nov; 98(11):1780-1790. PMID: 37665752.
      Citations: 4     Fields:    
    8. Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023 09 01; 108(9):2331-2342. PMID: 36951163; PMCID: PMC10483357.
      Citations: 2     Fields:    Translation:Humans
    9. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas. Cancer Cell. 2023 06 12; 41(6):1198. PMID: 37311416.
      Citations:    Fields:    
    10. Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023 04 13; 13(1):53. PMID: 37055414; PMCID: PMC10102188.
      Citations:    Fields:    Translation:Humans
    11. Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 2023 06; 37(6):1336-1348. PMID: 36977823; PMCID: PMC10244173.
      Citations:    Fields:    Translation:Humans
    12. Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 03 28; 7(6):933-942. PMID: 36322818; PMCID: PMC10027507.
      Citations: 6     Fields:    Translation:Humans
    13. El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma?variant. Virchows Arch. 2023 Jun; 482(6):1011-1019. PMID: 36864257.
      Citations:    Fields:    Translation:HumansCells
    14. El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524. PMID: 36933995.
      Citations:    Fields:    Translation:Humans
    15. Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, Dinardo C, Short NJ, Yilmaz M, Pemmaraju N, Takahashi K, Jabbour EJ, Pierce S, Konopleva M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022 Dec; 97(12):1599-1606. PMID: 36117258.
    16. Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJ. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022 Dec; 97(12):1560-1567. PMID: 36087091.
    17. Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022 11; 36(11):2729-2733. PMID: 36151141; PMCID: PMC9613474.
    18. Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, Sui D, Wei P, Khodakarami F, Tang Z, Routbort M, Bivins CA, Jabbour EJ, Medeiros LJ, Bhalla K, Kantarjian HM, Ravandi F, Khoury JD. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72. PMID: 35390143; PMCID: PMC9346958.
      Citations: 1     Fields:    Translation:Humans
    19. Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857. PMID: 35704787; PMCID: PMC9671758.
      Citations:    Fields:    
    20. Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res. 2022 08; 119:106884. PMID: 35691130.
      Citations:    Fields:    Translation:Humans
    21. Kannan S, Irwin ME, Herbrich SM, Cheng T, Patterson LL, Aitken MJL, Bhalla K, You MJ, Konopleva M, Zweidler-McKay PA, Chandra J. Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy. Antioxidants (Basel). 2022 Apr 05; 11(4). PMID: 35453402; PMCID: PMC9027903.
    22. Ma MCJ, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, Moore D, Akhter A, Hartert K, Jain N, Showell J, Ghosh S, Street L, Davidson M, Carey C, Tobin J, Perumal D, Vose JM, Lunning MA, Sohani AR, Chen BJ, Buckley S, Nastoupil LJ, Davis RE, Westin JR, Fowler NH, Parekh S, Gandhi M, Neelapu S, Stewart D, Bhalla K, Iqbal J, Greiner T, Rodig SJ, Mansoor A, Green MR. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica. 2022 03 01; 107(3):690-701. PMID: 33792219; PMCID: PMC8883549.
      Citations: 7     Fields:    Translation:Humans
    23. Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022 02 10; 139(6):907-921. PMID: 34601571; PMCID: PMC8832475.
      Citations: 1     Fields:    Translation:HumansCells
    24. Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, Daver N, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022 01 31; 12(1):23. PMID: 35102145; PMCID: PMC8803998.
      Citations:    Fields:    Translation:HumansAnimalsCells
    25. Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 01 11; 12(1):5. PMID: 35017466; PMCID: PMC8752621.
      Citations: 1     Fields:    Translation:HumansCells
    26. Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W, Tang Z, Alswailmi O, Bhalla KN, Qazilbash MH, Konopleva M, Khoury JD. Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel). 2021 Nov 23; 13(23). PMID: 34884997; PMCID: PMC8656770.
      Citations: 2     
    27. Sharma S, Bhalla K, Dayal S. Athena: Speciality Certificate Examination case for Paediatrics and Genetics. Clin Exp Dermatol. 2022 08; 47(8):1595-1596. PMID: 33904204.
      Citations:    Fields:    Translation:Humans
    28. Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98. PMID: 34016956; PMCID: PMC8138012.
      Citations: 5     Fields:    Translation:HumansCells
    29. Soldi R, Halder TG, Sampson S, Vankayalapati H, Weston A, Thode T, Bhalla KN, Ng S, Rodriguez Del Villar R, Drenner K, Kaadige MR, Horrigan SK, Batra SK, Salgia R, Sharma S. The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin ?-Like 1-?-Catenin Protein Complex. J Pharmacol Exp Ther. 2021 08; 378(2):77-86. PMID: 34006586.
      Citations: 2     Fields:    Translation:Humans
    30. Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi K. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607. PMID: 33972549; PMCID: PMC8110775.
      Citations: 12     Fields:    Translation:HumansCells
    31. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823. PMID: 33972555; PMCID: PMC8110810.
      Citations: 1     Fields:    
    32. Birdwell C, Fiskus W, Kadia TM, DiNardo CD, Mill CP, Bhalla KN. EVI1 dysregulation: impact on biology and therapy of myeloid malignancies. Blood Cancer J. 2021 03 22; 11(3):64. PMID: 33753715; PMCID: PMC7985498.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    33. Fiskus W, Mill CP, Perera D, Birdwell C, Deng Q, Yang H, Lara BH, Jain N, Burger J, Ferrajoli A, Davis JA, Saenz DT, Jin W, Coarfa C, Crews CM, Green MR, Khoury JD, Bhalla KN. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia. 2021 09; 35(9):2621-2634. PMID: 33654205; PMCID: PMC8410602.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    34. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213. PMID: 33585199; PMCID: PMC7878971.
      Citations: 5     
    35. Mehra S, Bhalla K, Dalal P, Gupta A, Nehra D. Coexistence of disseminated tuberculosis and peripheral deep vein thrombosis in a child with newly diagnosed celiac disease: A rare entity. J Family Med Prim Care. 2020 Dec; 9(12):6288-6290. PMID: 33681081; PMCID: PMC7928094.
    36. Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134. PMID: 33681815; PMCID: PMC7935111.
      Citations: 9     Fields:    Translation:Humans
    37. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996. PMID: 33214561; PMCID: PMC7677309.
      Citations: 3     Fields:    
    38. Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi K. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327. PMID: 33087716; PMCID: PMC7577981.
      Citations: 66     Fields:    Translation:HumansAnimals
    39. Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CD. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020 11; 95(11):E313-E315. PMID: 32804409.
      Citations:    Fields:    Translation:Humans
    40. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269. PMID: 32068780; PMCID: PMC7146021.
      Citations: 9     Fields:    Translation:HumansCells
    41. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Editor's Note: Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-mediated Potentiation of Bortezomib-induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells. Clin Cancer Res. 2020 03 15; 26(6):1531. PMID: 32169966.
      Citations:    Fields:    
    42. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020 06; 34(6):1588-1598. PMID: 31862959; PMCID: PMC7272263.
      Citations: 5     Fields:    Translation:HumansCells
    43. Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol. 2019 10; 43(10):1429-1437. PMID: 31261288.
      Citations: 15     Fields:    Translation:HumansCells
    44. Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020 02; 95(2):227-229. PMID: 31400013.
      Citations: 8     Fields:    Translation:Humans
    45. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K. Editor's Note: Cotreatment with STI-571 Enhances Tumor Necrosis Factor a-related Apoptosis-inducing Ligand (TRAIL or Apo-2L)-induced Apoptosis of Bcr-Abl-positive Human Acute Leukemia Cells. Clin Cancer Res. 2019 07 01; 25(13):4195. PMID: 31263034.
      Citations:    Fields:    
    46. Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR, Hartmann E, Rosenwald A. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med. 2019 06 19; 11(497). PMID: 31217338; PMCID: PMC6724184.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    47. Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73. PMID: 31023702; PMCID: PMC6609954.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    48. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4. PMID: 30647404; PMCID: PMC6333829.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    49. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN, Soldi R, Horrigan S. Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386. PMID: 30575820.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    50. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019 01; 94(1):74-79. PMID: 30328139; PMCID: PMC6570401.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    51. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674. PMID: 30185431; PMCID: PMC6265645.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    52. DiNardo AR, Nishiguchi T, Mace EM, Rajapakshe K, Mtetwa G, Kay A, Maphalala G, Secor WE, Mejia R, Orange JS, Coarfa C, Bhalla KN, Graviss EA, Mandalakas AM, Makedonas G. Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes. J Immunol. 2018 07 01; 201(1):124-133. PMID: 29752313; PMCID: PMC6008220.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    53. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE, Nogueras-Gonz?lez GM. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48. PMID: 29741984; PMCID: PMC6226369.
      Citations: 27     Fields:    Translation:Humans
    54. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407. PMID: 29218851.
      Citations: 126     Fields:    Translation:HumansCells
    55. Verstovsek S, Fiskus W, Manshouri T, Bhalla KN. Targeting cistrome and dysregulated transcriptome of post-MPN sAML. Oncotarget. 2017 Nov 07; 8(55):93301-93302. PMID: 29212143; PMCID: PMC5706789.
      Citations: 5     Fields:    
    56. Benton CB, Fiskus W, Bhalla KN. Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer. Cancer J. 2017 Sep/Oct; 23(5):286-291. PMID: 28926429.
      Citations: 11     Fields:    Translation:HumansCells
    57. Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci. 2017 Jul 26; 18(8). PMID: 28933735; PMCID: PMC5578010.
      Citations: 11     Fields:    Translation:HumansCells
    58. Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 25; 1(17):1312-1323. PMID: 29296774; PMCID: PMC5727976.
      Citations: 26     Fields:    
    59. Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 2018 02; 32(2):343-352. PMID: 28663582.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    60. Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Res Treat. 2017 Sep; 165(2):375-382. PMID: 28623430; PMCID: PMC5682621.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    61. Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. Leukemia. 2018 01; 32(1):49-60. PMID: 28579617; PMCID: PMC5716937.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    62. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017 Aug 15; 123(16):3050-3060. PMID: 28387922; PMCID: PMC5544569.
      Citations: 15     Fields:    Translation:Humans
    63. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, Iyer SP, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2017 07; 31(7):1658. PMID: 28322226.
      Citations: 6     Fields:    
    64. Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia. 2017 09; 31(9):1951-1961. PMID: 28042144; PMCID: PMC5537055.
      Citations: 72     Fields:    Translation:HumansAnimalsCells
    65. Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. 2017 03; 102(3):519-528. PMID: 27927766; PMCID: PMC5394958.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    66. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85a, androgen receptor, and Src. J Biol Chem. 2016 10 21; 291(43):22841. PMID: 27825079; PMCID: PMC5077216.
      Citations:    Fields:    
    67. Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017 03; 31(3):678-687. PMID: 27677740; PMCID: PMC5345582.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    68. Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, Mumm JS, Melnick AM, Bhalla KN. SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. Cancer Res. 2016 09 15; 76(18):5467-78. PMID: 27503926; PMCID: PMC5345574.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    69. Bhalla KN, Fiskus W. NEDD8 and HDACs: promising cotargets in AML. Blood. 2016 05 05; 127(18):2168-70. PMID: 27151736; PMCID: PMC4859193.
      Citations:    Fields:    
    70. DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2. PMID: 27210295; PMCID: PMC4925265.
      Citations: 31     Fields:    Translation:Humans
    71. Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015 Sep 24; 126(13):1565-74. PMID: 26254443; PMCID: PMC4582333.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    72. Padia J, Bhalla K, Verma A, Soldi R, Horrigan SK, Cholody MW, Sorna V, Bearss J, Gilcrease G, Vankayalapati H, Sharma S. Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime ?-Catenin Pathway Inhibitors. J Med Chem. 2015 Aug 13; 58(15):5854-62. PMID: 26182238.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    73. Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, Agrawal M, Nichols G, Middleton S, Beryozkina A, Sarapa N, Peck R, Zhi J. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015 Sep; 76(3):587-95. PMID: 26210682.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    74. Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, Sharma S, Bradner JE, Bhalla KN. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia. 2016 Feb; 30(2):504-8. PMID: 26148704; PMCID: PMC4809433.
      Citations: 22     Fields:    Translation:HumansAnimals
    75. Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN. Pre-clinical efficacy of combined therapy with novel ?-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2015 Jun; 29(6):1267-78. PMID: 25482131; PMCID: PMC4456205.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    76. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014 Jul 30; 5(14):5637-50. PMID: 25026298; PMCID: PMC4170637.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    77. Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther. 2014 Oct; 13(10):2315-27. PMID: 25053825; PMCID: PMC4185220.
      Citations: 81     Fields:    Translation:HumansAnimalsCells
    78. Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul; 146(1):145-52. PMID: 24903226.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    79. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014 Nov; 28(11):2155-64. PMID: 24699304; PMCID: PMC4739780.
      Citations: 113     Fields:    Translation:HumansAnimalsCells
    80. Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, Chauhan L, Rao R, Gunewardena S, Schorno K, Austin CP, Maddocks K, Byrd J, Melnick A, Huang P, Wiestner A, Bhalla KN. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 2014 May 01; 74(9):2520-32. PMID: 24599128; PMCID: PMC4172421.
      Citations: 94     Fields:    Translation:HumansAnimalsCells
    81. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014 May; 13(5):1142-54. PMID: 24435446.
      Citations: 94     Fields:    Translation:HumansAnimalsCells
    82. Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R. Advances in myelofibrosis: a clinical case approach. Haematologica. 2013 Oct; 98(10):1499-509. PMID: 24091929; PMCID: PMC3789453.
      Citations: 5     Fields:    Translation:HumansAnimals
    83. Williams CB, Kambhampati S, Fiskus W, Wick J, Dutreix C, Ganguly S, Aljitawi O, Reyes R, Fleming A, Abhyankar S, Bhalla KN, McGuirk JP. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacotherapy. 2013 Dec; 33(12):1341-52. PMID: 23798029.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    84. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, Bailey S, Chica S, Banerji U. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 2013 Jul 01; 19(13):3671-80. PMID: 23757357.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    85. DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, Ritchie EK, Snyder DS, Begna K, Ganguly S, Ondovik MS, Rine J, Bhalla KN. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013 Aug; 162(3):326-35. PMID: 23701016.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    86. Yang Y, Fiskus W, Yong B, Atadja P, Takahashi Y, Pandita TK, Wang HG, Bhalla KN. Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6841-6. PMID: 23569248; PMCID: PMC3637746.
      Citations: 89     Fields:    Translation:HumansAnimalsCells
    87. Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J, Bhalla KN. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther. 2013 May; 12(5):577-88. PMID: 23445613.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    88. DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013 Aug; 27(8):1628-36. PMID: 23385375.
      Citations: 54     Fields:    Translation:HumansCellsCTClinical Trials
    89. Burns TA, Subathra M, Signorelli P, Choi Y, Yang X, Wang Y, Villani M, Bhalla K, Zhou D, Luberto C. Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene. J Lipid Res. 2013 Mar; 54(3):794-805. PMID: 23160178; PMCID: PMC3617953.
      Citations: 13     Fields:    Translation:HumansCells
    90. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr; 27(4):907-13. PMID: 23174881; PMCID: PMC4140185.
      Citations: 7     Fields:    Translation:Humans
    91. Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget. 2012 Nov; 3(11):1416-27. PMID: 23232026; PMCID: PMC3717802.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    92. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012 Oct 16; 22(4):506-523. PMID: 23079660; PMCID: PMC3973134.
      Citations: 144     Fields:    Translation:HumansAnimalsCells
    93. Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E, Mudunuru U, Smith JE, Hembruff SL, Atadja P, Marquez VE, Bhalla K. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res. 2012 Nov 15; 18(22):6227-38. PMID: 22932665; PMCID: PMC4113119.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    94. Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. Role of additional novel therapies in myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2012 Oct; 26(5):959-80. PMID: 23009932.
      Citations: 6     Fields:    Translation:HumansCells
    95. Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC, Bhalla KN. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Res Treat. 2012 Sep; 135(2):433-44. PMID: 22825030.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    96. Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Am J Hematol. 2012 May; 87(5):562-8. PMID: 22460584; PMCID: PMC3491640.
      Citations: 13     Fields:    Translation:HumansCells
    97. Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja P, Bhalla KN. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012 Apr; 11(4):973-83. PMID: 22367781.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    98. Walker SL, Ariga J, Mathias JR, Coothankandaswamy V, Xie X, Distel M, Parsons MJ, Bhalla KN, Saxena MT, Mumm JS, K?ster RW. Automated reporter quantification in vivo: high-throughput screening method for reporter-based assays in zebrafish. PLoS One. 2012; 7(1):e29916. PMID: 22238673; PMCID: PMC3251595.
      Citations: 40     Fields:    Translation:Animals
    99. Rao R, Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. HDAC inhibitors and chaperone function. Adv Cancer Res. 2012; 116:239-62. PMID: 23088873.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    100. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang E, Luu T, Somlo G, Goetz M, Swaby R, Shapiro CL, Stearns V, Christos P, Espinoza-Delgado I, Bhalla K, Sparano JA. Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 2012 Apr; 132(3):1063-72. PMID: 22200869; PMCID: PMC3486521.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    101. Ustun C, Savage NM, Gotlib J, Bhalla K, Manaloor E, George TI. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review. Am J Hematol. 2012 Feb; 87(2):191-3. PMID: 22081475.
      Citations: 2     Fields:    Translation:HumansCells
    102. Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S, Rao NN, Ha K, Smith JE, Hembruff SL, Abhyankar S, McGuirk J, Bhalla KN. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res. 2011 Dec 01; 17(23):7347-58. PMID: 21976548; PMCID: PMC3743080.
      Citations: 56     Fields:    Translation:HumansAnimalsCells
    103. Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U, Ma H, Chen L, Venkannagari S, Ha K, Abhyankar S, Williams C, McGuirk J, Khoury HJ, Ustun C, Bhalla KN. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood. 2011 Sep 15; 118(11):3096-106. PMID: 21719597; PMCID: PMC6710561.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    104. Arellano M, Winton E, Pan L, Lima L, Tighiouart M, Bhalla K, Heffner LT, Neely J, Hutcherson D, McLemore M, Langston A, Khoury HJ. High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years. Cancer. 2012 Jan 15; 118(2):428-33. PMID: 21717443.
      Citations: 5     Fields:    Translation:Humans
    105. Ha K, Fiskus W, Rao R, Balusu R, Venkannagari S, Nalabothula NR, Bhalla KN. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Mol Cancer Ther. 2011 Jul; 10(7):1194-206. PMID: 21566061.
      Citations: 36     Fields:    Translation:HumansCells
    106. Hu X, Yang D, Zimmerman M, Liu F, Yang J, Kannan S, Burchert A, Szulc Z, Bielawska A, Ozato K, Bhalla K, Liu K. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res. 2011 Apr 15; 71(8):2882-91. PMID: 21487040; PMCID: PMC3078194.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    107. Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol. 2011 Apr 01; 186(7):3986-96. PMID: 21368229; PMCID: PMC3998678.
      Citations: 29     Fields:    Translation:AnimalsCells
    108. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27; 117(4):1141-5. PMID: 21098399; PMCID: PMC4916554.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    109. Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest. 2010 Dec 01; 120(12):4569-82. PMID: 21041953; PMCID: PMC2993589.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    110. Ha K, Lee GE, Palii SS, Brown KD, Takeda Y, Liu K, Bhalla KN, Robertson KD. Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum Mol Genet. 2011 Jan 01; 20(1):126-40. PMID: 20940144; PMCID: PMC3000680.
      Citations: 50     Fields:    Translation:HumansCells
    111. Choi JH, Li Y, Guo J, Pei L, Rauch TA, Kramer RS, Macmil SL, Wiley GB, Bennett LB, Schnabel JL, Taylor KH, Kim S, Xu D, Sreekumar A, Pfeifer GP, Roe BA, Caldwell CW, Bhalla KN, Shi H. Genome-wide DNA methylation maps in follicular lymphoma cells determined by methylation-enriched bisulfite sequencing. PLoS One. 2010 Sep 29; 5(9). PMID: 20927367; PMCID: PMC2947499.
      Citations: 20     Fields:    Translation:HumansCells
    112. Mandawat A, Fiskus W, Buckley KM, Robbins K, Rao R, Balusu R, Navenot JM, Wang ZX, Ustun C, Chong DG, Atadja P, Fujii N, Peiper SC, Bhalla K. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood. 2010 Dec 09; 116(24):5306-15. PMID: 20810927.
      Citations: 21     Fields:    Translation:HumansCells
    113. Rao R, Nalluri S, Fiskus W, Balusu R, Joshi A, Mudunuru U, Buckley KM, Robbins K, Ustun C, Reuther GW, Bhalla KN. Heat shock protein 90 inhibition depletes TrkA levels and signaling in human acute leukemia cells. Mol Cancer Ther. 2010 Aug; 9(8):2232-42. PMID: 20663926; PMCID: PMC3008427.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    114. Rao R, Nalluri S, Fiskus W, Savoie A, Buckley KM, Ha K, Balusu R, Joshi A, Coothankandaswamy V, Tao J, Sotomayor E, Atadja P, Bhalla KN. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res. 2010 Oct 01; 16(19):4742-54. PMID: 20647473; PMCID: PMC2948590.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    115. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound ?-phenylethyl isothiocyanate. Blood. 2010 Oct 14; 116(15):2732-41. PMID: 20566897; PMCID: PMC3324257.
      Citations: 48     Fields:    Translation:HumansCells
    116. Rao R, Nalluri S, Kolhe R, Yang Y, Fiskus W, Chen J, Ha K, Buckley KM, Balusu R, Coothankandaswamy V, Joshi A, Atadja P, Bhalla KN. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):942-52. PMID: 20371724.
      Citations: 33     Fields:    Translation:HumansCells
    117. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010 Apr; 24(4):699-705. PMID: 20111068.
      Citations: 62     Fields:    Translation:HumansCellsCTClinical Trials
    118. Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR, Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN, Schoenlein PV. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy. 2010 Jan; 6(1):19-35. PMID: 20110775.
      Citations: 27     Fields:    Translation:HumansCells
    119. Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009 Dec; 15(12):1369-76. PMID: 19966776; PMCID: PMC2805915.
      Citations: 80     Fields:    Translation:HumansCells
    120. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, Joshi A, Balusu R, Koul S, Chen J, Savoie A, Ustun C, Jillella AP, Atadja P, Levine RL, Bhalla KN. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009 Dec 03; 114(24):5024-33. PMID: 19828702; PMCID: PMC2788976.
      Citations: 74     Fields:    Translation:HumansAnimalsCells
    121. Ustun C, DeRemer DL, Jillella AP, Bhalla KN. Investigational drugs targeting FLT3 for leukemia. Expert Opin Investig Drugs. 2009 Oct; 18(10):1445-56. PMID: 19671038.
      Citations: 3     Fields:    Translation:HumansAnimals
    122. Robertson KD, Bhalla KN. Missteps in "tango" for epigenome targeting. Blood. 2009 Sep 24; 114(13):2569-70. PMID: 19779044.
      Citations: 1     Fields:    
    123. Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol. 2009 Oct; 147(1):97-101. PMID: 19663825.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    124. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE, Bhalla KN. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009 Sep 24; 114(13):2733-43. PMID: 19638619; PMCID: PMC2756128.
      Citations: 164     Fields:    Translation:HumansCells
    125. Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN. Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. Cancer Biol Ther. 2009 Jul; 8(13):1273-80. PMID: 19440035; PMCID: PMC2766923.
      Citations: 10     Fields:    Translation:HumansCells
    126. Bhalla K, Naghavi M, Shahraz S, Bartels D, Murray CJ. Building national estimates of the burden of road traffic injuries in developing countries from all available data sources: Iran. Inj Prev. 2009 Jun; 15(3):150-6. PMID: 19494093.
      Citations: 49     Fields:    Translation:Humans
    127. Fiskus W, Buckley K, Rao R, Mandawat A, Yang Y, Joshi R, Wang Y, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Atadja P, Bhalla KN. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther. 2009 May; 8(10):939-50. PMID: 19279403; PMCID: PMC2775142.
      Citations: 41     Fields:    Translation:HumansCells
    128. Buckley K, Fiskus W, Bhalla K. Activation of mTOR: A new mechanism "PIMed". Cancer Biol Ther. 2009 May; 8(9):854-5. PMID: 19363296.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    129. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ. Targeting HSP90 for cancer therapy. Br J Cancer. 2009 May 19; 100(10):1523-9. PMID: 19401686; PMCID: PMC2696754.
      Citations: 105     Fields:    Translation:Humans
    130. Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, Hung MC, Wang HG. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem. 2009 Apr 24; 284(17):11171-83. PMID: 19265193; PMCID: PMC2670122.
      Citations: 66     Fields:    Translation:HumansCells
    131. Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R, Lee P, Joshi R, Yang Y, Kolhe R, Balusu R, Chappa P, Natarajan K, Jillella A, Atadja P, Bhalla KN. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood. 2009 Apr 23; 113(17):4038-48. PMID: 19074726.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    132. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009 Jan; 10(1):92-100. PMID: 19011628; PMCID: PMC3925685.
      Citations: 170     Fields:    Translation:HumansAnimalsCells
    133. Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, Lewis G, Ramalingam P, Kepten I, Jillella A, Bhalla K. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res. 2009 May; 33(5):735-41. PMID: 18986703.
      Citations: 16     Fields:    Translation:Humans
    134. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, Kolhe R, Balusu R, Eaton K, Lee P, Ustun C, Jillella A, Buser CA, Peiper S, Bhalla K. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 2008 Oct 01; 14(19):6106-15. PMID: 18829489; PMCID: PMC2665710.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    135. Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, Kolhe R, Mandawat A, Wang Y, Joshi R, Eaton K, Lee P, Atadja P, Peiper S, Bhalla K. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood. 2008 Oct 01; 112(7):2896-905. PMID: 18660379.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    136. Rao R, Fiskus W, Yang Y, Lee P, Joshi R, Fernandez P, Mandawat A, Atadja P, Bradner JE, Bhalla K. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood. 2008 Sep 01; 112(5):1886-93. PMID: 18591380.
      Citations: 82     Fields:    Translation:HumansCells
    137. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J, Atadja P, Bhalla K. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res. 2008 Jun 15; 68(12):4833-42. PMID: 18559531; PMCID: PMC2665713.
      Citations: 105     Fields:    Translation:HumansCells
    138. Kimmick GG, Cirrincione C, Duggan DB, Bhalla K, Robert N, Berry D, Norton L, Lemke S, Henderson IC, Hudis C, Winer E, Cancer and Leukemia Group B. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009 Feb; 113(3):479-90. PMID: 18306034; PMCID: PMC4217205.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    139. Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F, Albitar M. An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res. 2008 Jun; 32(6):936-43. PMID: 18155764.
      Citations: 4     Fields:    Translation:HumansCells
    140. Woods NT, Yamaguchi H, Lee FY, Bhalla KN, Wang HG. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res. 2007 Nov 15; 67(22):10744-52. PMID: 18006817; PMCID: PMC2258556.
      Citations: 44     Fields:    Translation:HumansAnimalsCells
    141. Yang Y, Fu W, Chen J, Olashaw N, Zhang X, Nicosia SV, Bhalla K, Bai W. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol. 2007 Nov; 9(11):1253-62. PMID: 17934453; PMCID: PMC3201724.
      Citations: 149     Fields:    Translation:HumansAnimalsCells
    142. Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res. 2008 Apr; 32(4):643-9. PMID: 17900686.
      Citations: 7     Fields:    Translation:HumansCells
    143. Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther. 2007 Sep; 6(9):2515-24. PMID: 17876048.
      Citations: 51     Fields:    Translation:HumansCells
    144. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15; 110(10):3540-6. PMID: 17715389.
      Citations: 220     Fields:    Translation:HumansCTClinical Trials
    145. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res. 2007 Aug 15; 13(16):4882-90. PMID: 17699868.
      Citations: 71     Fields:    Translation:HumansCells
    146. Khaki P, Bhalla P, Sharma P, Chawla R, Bhalla K. Epidemilogical analysis of Neisseria gonorrhoeae isolates by antimicrobial susceptibility testing, auxotyping and serotyping. Indian J Med Microbiol. 2007 Jul; 25(3):225-9. PMID: 17901639.
      Citations: 4     Fields:    Translation:HumansCells
    147. O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M, National Comprehensive Cancer Network. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007 May; 5(5):474-96. PMID: 17509252.
      Citations: 2     Fields:    Translation:HumansCells
    148. Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther. 2007 Apr; 6(4):1400-5. PMID: 17431118.
      Citations: 38     Fields:    Translation:HumansCells
    149. Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther. 2006 Dec; 5(12):3096-104. PMID: 17172412.
      Citations: 45     Fields:    Translation:HumansCells
    150. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006 Oct 01; 12(19):5869-78. PMID: 17020995.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    151. Ma W, Kantarjian H, Jilani I, Gorre M, Bhalla K, Ottmann O, Giles F, Albitar M. Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. Leukemia. 2006 Nov; 20(11):1989-91. PMID: 16932346.
      Citations: 4     Fields:    Translation:Humans
    152. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006 Aug 01; 12(15):4628-35. PMID: 16899611.
      Citations: 121     Fields:    Translation:HumansCTClinical Trials
    153. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006 Jul 01; 66(13):6512-20. PMID: 16818622.
      Citations: 84     Fields:    Translation:HumansCells
    154. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15; 354(24):2542-51. PMID: 16775235.
      Citations: 382     Fields:    Translation:HumansCTClinical Trials
    155. Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res. 2006 Apr 15; 66(8):4309-18. PMID: 16618756.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    156. Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 2006 Jul 15; 108(2):645-52. PMID: 16537804.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    157. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006 May; 69(5):1527-33. PMID: 16436588.
      Citations: 41     Fields:    Translation:AnimalsCells
    158. Demidenko ZN, Vivo C, Halicka HD, Li CJ, Bhalla K, Broude EV, Blagosklonny MV. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death Differ. 2006 Sep; 13(9):1434-41. PMID: 16311509.
      Citations: 39     Fields:    Translation:HumansCells
    159. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ES, Lawrence N, Bhalla K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 2005 Nov 15; 65(22):10536-44. PMID: 16288046.
      Citations: 85     Fields:    Translation:HumansCells
    160. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 2006 Mar 15; 107(6):2501-6. PMID: 16291594; PMCID: PMC1895739.
      Citations: 31     Fields:    Translation:HumansCells
    161. O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M. Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):732-55. PMID: 16316611.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    162. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005 Sep; 4(9):1311-9. PMID: 16170022.
      Citations: 37     Fields:    Translation:HumansCells
    163. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005 Sep 01; 11(17):6382-9. PMID: 16144943.
      Citations: 67     Fields:    Translation:HumansCells
    164. Swaby RF, Bhalla KN. Importance of rational pre-clinical development: gemcitabine comes of age. Cancer Biol Ther. 2005 Aug; 4(8):872-3. PMID: 16103749.
      Citations:    Fields:    Translation:HumansAnimalsCells
    165. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005 Jul 22; 280(29):26729-34. PMID: 15937340.
      Citations: 335     Fields:    Translation:HumansCells
    166. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005 Jun 10; 23(17):3971-93. PMID: 15897549.
      Citations: 94     Fields:    Translation:HumansCells
    167. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005 Jan 15; 65(2):613-21. PMID: 15695406.
      Citations: 292     Fields:    Translation:HumansCells
    168. Bhalla K, List A. Histone deacetylase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Dec; 17(4):595-611. PMID: 15494297.
      Citations: 8     Fields:    Translation:Humans
    169. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005 Feb 15; 105(4):1768-76. PMID: 15514006.
      Citations: 101     Fields:    Translation:HumansCells
    170. Staley CA, Harris WB, Landry J, Small W, Kooby D, Gillespie TW, Meyers M, Bhalla KN. Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies. Surg Oncol Clin N Am. 2004 Oct; 13(4):697-709, x. PMID: 15350943.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    171. Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor EM. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood. 2005 Feb 01; 105(3):1135-43. PMID: 15454486.
      Citations: 30     Fields:    Translation:AnimalsCells
    172. Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, Annavarapu S, Mouttaki A, Sondarva G, Wei S, Wu J, Djeu J, Bhalla K. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood. 2005 Feb 01; 105(3):1246-55. PMID: 15388581.
      Citations: 53     Fields:    Translation:HumansCells
    173. Gasparetto M, Gentry T, Sebti S, O'Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J, Smith C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. J Immunol Methods. 2004 Sep; 292(1-2):59-71. PMID: 15350512.
      Citations: 17     Fields:    Translation:HumansCells
    174. Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res. 2004 Aug 01; 10(15):4991-7. PMID: 15297399.
      Citations: 37     Fields:    Translation:HumansCells
    175. Yamaguchi H, Chen J, Bhalla K, Wang HG. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem. 2004 Sep 17; 279(38):39431-7. PMID: 15262986.
      Citations: 40     Fields:    Translation:HumansCells
    176. George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 2004 May 15; 64(10):3645-52. PMID: 15150124.
      Citations: 38     Fields:    Translation:HumansCells
    177. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 2004 Apr 01; 64(7):2580-9. PMID: 15059915.
      Citations: 53     Fields:    Translation:HumansCells
    178. Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp. 2004; 259:249-66; discussion 266-8, 285-8. PMID: 15171259.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    179. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003 Dec 08; 22(56):9075-86. PMID: 14663486.
      Citations: 128     Fields:    Translation:HumansCells
    180. Nimmanapalli R, Bali P, O'Bryan E, Fuino L, Guo F, Wu J, Houghton P, Bhalla K. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res. 2003 Nov 15; 63(22):7950-8. PMID: 14633726.
      Citations: 13     Fields:    Translation:HumansCells
    181. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther. 2003 Oct; 2(10):971-84. PMID: 14578462.
      Citations: 74     Fields:    Translation:HumansCells
    182. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem. 2003 Oct 31; 278(44):42992-3000. PMID: 12933816.
      Citations: 69     Fields:    Translation:HumansCells
    183. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003 Aug 15; 63(16):5126-35. PMID: 12941844.
      Citations: 76     Fields:    Translation:HumansCells
    184. Griffin D, Wittmann S, Guo F, Nimmanapalli R, Bali P, Wang HG, Bhalla K. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecol Oncol. 2003 Apr; 89(1):37-47. PMID: 12694652.
      Citations: 5     Fields:    Translation:HumansCells
    185. Yamaguchi H, Bhalla K, Wang HG. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Cancer Res. 2003 Apr 01; 63(7):1483-9. PMID: 12670894.
      Citations: 35     Fields:    Translation:HumansCells
    186. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood. 2003 Jul 01; 102(1):269-75. PMID: 12623837.
      Citations: 24     Fields:    Translation:HumansCells
    187. Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, Huang M, Jove R, Wang HG, Bhalla K. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. 2003 Jan 01; 63(1):93-9. PMID: 12517783.
      Citations: 23     Fields:    Translation:HumansCells
    188. Nimmanapalli R, Bhalla K. Targets in apoptosis signaling: promise of selective anticancer therapy. Methods Mol Biol. 2003; 223:465-83. PMID: 12777745.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    189. Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002 Dec 12; 21(57):8804-16. PMID: 12483533.
      Citations: 37     Fields:    Translation:HumansCells
    190. Nimmanapalli R, Bhalla K. Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. Oncogene. 2002 Dec 09; 21(56):8584-90. PMID: 12476305.
      Citations: 5     Fields:    Translation:HumansCells
    191. Guo F, Bhalla K. The FLIP variation on the TRAIL DISC: doxorubicin conducts the swan song. Cancer Biol Ther. 2002 Sep-Oct; 1(5):528-9. PMID: 12496482.
      Citations: 1     Fields:    Translation:Humans
    192. Mukhopadhyay A, Shishodia S, Suttles J, Brittingham K, Lamothe B, Nimmanapalli R, Bhalla KN, Aggarwal BB. Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors. J Biol Chem. 2002 Aug 23; 277(34):30622-8. PMID: 12060665.
      Citations: 4     Fields:    Translation:HumansCells
    193. O'Dwyer ME, Nimmanapalli R, Bhalla KN, Druker BJ, La Ros?e P. Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Semin Hematol. 2002 Apr; 39(2 Suppl 1):18-21. PMID: 12012318.
      Citations: 4     Fields:    
    194. Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res. 2002 Jan 15; 62(2):466-71. PMID: 11809697.
      Citations: 20     Fields:    Translation:HumansCells
    195. Porosnicu M, Nimmanapalli R, Nguyen D, Worthington E, Perkins C, Bhalla KN. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia. 2001 May; 15(5):772-8. PMID: 11368438.
      Citations: 8     Fields:    Translation:HumansCells
    196. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001 Mar 01; 61(5):1799-804. PMID: 11280726.
      Citations: 60     Fields:    Translation:HumansCells
    197. Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O'Bryan E, Perkins C, Bhalla K. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res. 2001 Feb; 7(2):350-7. PMID: 11234890.
      Citations: 14     Fields:    Translation:HumansCells
    198. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood. 2000 Dec 01; 96(12):3900-6. PMID: 11090076.
      Citations: 27     Fields:    Translation:HumansCells
    199. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood. 2000 Sep 15; 96(6):2246-53. PMID: 10979973.
      Citations: 35     Fields:    Translation:HumansCells
    200. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 2000 Mar 15; 60(6):1645-53. PMID: 10749135.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    201. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000 Feb 01; 95(3):1014-22. PMID: 10648417.
      Citations: 38     Fields:    Translation:HumansCells
    202. Balachandran S, Roberts PC, Kipperman T, Bhalla KN, Compans RW, Archer DR, Barber GN. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol. 2000 Feb; 74(3):1513-23. PMID: 10627563; PMCID: PMC111487.
      Citations: 94     Fields:    Translation:AnimalsCells
    203. Cai J, Zheng T, Masood R, Smith DL, Hinton DR, Kim CN, Fang G, Bhalla K, Gill PS. Paclitaxel Induces Apoptosis in AIDS-Related Kaposi's Sarcoma Cells. Sarcoma. 2000; 4(1-2):37-45. PMID: 18521433; PMCID: PMC2408359.
      Citations: 4     
    204. Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res. 1999 Jul; 5(7):1723-30. PMID: 10430075.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    205. Kim CN, Bhalla K, Kreitman RJ, Willingham MC, Hall P, Tagge EP, Jia T, Frankel AE. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leuk Res. 1999 Jun; 23(6):527-38. PMID: 10374846.
      Citations: 2     Fields:    Translation:HumansCells
    206. Han Z, Bhalla K, Pantazis P, Hendrickson EA, Wyche JH. Cif (Cytochrome c efflux-inducing factor) activity is regulated by Bcl-2 and caspases and correlates with the activation of Bid. Mol Cell Biol. 1999 Feb; 19(2):1381-9. PMID: 9891071; PMCID: PMC116066.
      Citations: 5     Fields:    Translation:HumansCells
    207. Burri SH, Kim CN, Fang G, Chang BS, Perkins C, Harris W, Davis LW, Thompson CB, Bhalla KN. 'Loop' domain deletional mutant of Bcl-xL is as effective as p29Bcl-xL in inhibiting radiation-induced cytosolic accumulation of cytochrome c (cyt c), caspase-3 activity, and apoptosis. Int J Radiat Oncol Biol Phys. 1999 Jan 15; 43(2):423-30. PMID: 10030271.
      Citations: 5     Fields:    Translation:HumansCells
    208. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J. 1998 Dec 01; 17(23):6888-902. PMID: 9843495; PMCID: PMC1171037.
      Citations: 115     Fields:    Translation:AnimalsCells
    209. Ibrado AM, Kim CN, Bhalla K. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells. Leukemia. 1998 Dec; 12(12):1930-6. PMID: 9844922.
      Citations: 17     Fields:    Translation:HumansCells
    210. Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res. 1998 Oct 15; 58(20):4561-6. PMID: 9788601.
      Citations: 20     Fields:    Translation:HumansCells
    211. Fang G, Chang BS, Kim CN, Perkins C, Thompson CB, Bhalla KN. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res. 1998 Aug 01; 58(15):3202-8. PMID: 9699642.
      Citations: 21     Fields:    Translation:HumansCells
    212. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998 May; 16(5):1826-34. PMID: 9586897.
      Citations: 53     Fields:    Translation:HumansCTClinical Trials
    213. Bhalla K, Harris WB. Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer. Semin Oncol. 1998 Apr; 25(2 Suppl 3):19-24. PMID: 9566203.
      Citations: 2     Fields:    Translation:Humans
    214. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998 Mar 01; 91(5):1700-5. PMID: 9473236.
      Citations: 56     Fields:    Translation:HumansCells
    215. Fontana JA, Sun RJ, Rishi AK, Dawson MI, Zhang Y, Tschang SH, Bhalla K, Han Z, Wyche J, Poirer G, Sheikh MS, Shroot B, Reichert U, Ord?nez JV. Overexpression of bcl-2 or bcl-XL fails to inhibit apoptosis mediated by a novel retinoid. Oncol Res. 1998; 10(6):313-24. PMID: 9848102.
      Citations:    Fields:    Translation:HumansCells
    216. Frankel AE, Hall PD, Burbage C, Vesely J, Willingham M, Bhalla K, Kreitman RJ. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 1997 Nov 01; 90(9):3654-61. PMID: 9345050.
      Citations: 4     Fields:    Translation:HumansCells
    217. Kim CN, Wang X, Huang Y, Ibrado AM, Liu L, Fang G, Bhalla K. Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res. 1997 Aug 01; 57(15):3115-20. PMID: 9242435.
      Citations: 41     Fields:    Translation:HumansCells
    218. Ibrado AM, Liu L, Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res. 1997 Mar 15; 57(6):1109-15. PMID: 9067280.
      Citations: 17     Fields:    Translation:HumansCells
    219. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997 Feb 21; 275(5303):1129-32. PMID: 9027314.
      Citations: 1002     Fields:    Translation:HumansCells
    220. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 1997 Feb; 11(2):253-7. PMID: 9009089.
      Citations: 20     Fields:    Translation:HumansCells
    221. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat. 1997 Jan; 42(1):73-81. PMID: 9116321.
      Citations: 29     Fields:    Translation:HumansCells
    222. Ray S, Bullock G, Tang C, Ibrado AM, Huang Y, Bhalla K, Nu?ez G. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ. 1996 Dec; 7(12):1617-23. PMID: 8959329.
      Citations: 5     Fields:    Translation:HumansCells
    223. Bullock G, Ray S, Reed JC, Krajewski S, Ibrado AM, Huang Y, Bhalla K. Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein. Leukemia. 1996 Nov; 10(11):1731-40. PMID: 8892676.
      Citations: 1     Fields:    Translation:HumansCells
    224. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res. 1996 Oct 15; 56(20):4743-8. PMID: 8840993.
      Citations: 21     Fields:    Translation:HumansCells
    225. Ibrado AM, Huang Y, Fang G, Bhalla K. Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differ. 1996 Aug; 7(8):1087-94. PMID: 8853905.
      Citations: 7     Fields:    Translation:HumansCells
    226. Bhalla K, Ibrado AM, Bradt JE, Ray S, Huang Y, Tang C, Nawabi A, Hoffman R. pIXY321 protects against Ara-C or taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow progenitor cells. Leukemia. 1995 Nov; 9(11):1851-6. PMID: 7475274.
      Citations: 1     Fields:    Translation:HumansCells
    227. Ponnathpur V, Ibrado AM, Reed JC, Ray S, Huang Y, Self S, Bullock G, Nawabi A, Bhalla K. Effects of modulators of protein kinases on taxol-induced apoptosis of human leukemic cells possessing disparate levels of p26BCL-2 protein. Clin Cancer Res. 1995 Nov; 1(11):1399-406. PMID: 9815937.
      Citations: 2     Fields:    Translation:HumansCells
    228. Bullock G, Ray S, Reed J, Miyashita T, Maria Ibrado A, Huang Y, Bhalla K. Evidence against a direct role for the induction of c-jun expression in the mediation of drug-induced apoptosis in human acute leukemia cells. Clin Cancer Res. 1995 May; 1(5):559-64. PMID: 9816016.
      Citations: 2     Fields:    Translation:HumansCells
    229. Walle T, Walle UK, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos. 1995 Apr; 23(4):506-12. PMID: 7600920.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    230. Kumar G, Ray S, Walle T, Huang Y, Willingham M, Self S, Bhalla K. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol. Cancer Chemother Pharmacol. 1995; 36(2):129-35. PMID: 7767949.
      Citations: 11     Fields:    Translation:HumansCells
    231. Tang C, Huang Y, Ponnathpur VS, Ray S, Mahoney ME, Bullock G, Ibrado AM, Bhalla K. Combined antileukemic activity of pIXY 321 and Ara-C against human acute myeloid leukemia cells. Leuk Lymphoma. 1994 Nov; 15(5-6):445-51. PMID: 7874002.
      Citations: 1     Fields:    Translation:HumansCells
    232. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia. 1994 Nov; 8(11):1960-9. PMID: 7526093.
      Citations: 20     Fields:    Translation:Cells
    233. Liu Y, Bhalla K, Hill C, Priest DG. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem Pharmacol. 1994 Sep 15; 48(6):1265-72. PMID: 7945420.
      Citations: 21     Fields:    Translation:HumansCells
    234. Willingham MC, Bhalla K. Transient mitotic phase localization of bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis. J Histochem Cytochem. 1994 Apr; 42(4):441-50. PMID: 7907352.
      Citations: 10     Fields:    Translation:Humans
    235. Brandt JE, Bhalla K, Hoffman R. Effects of interleukin-3 and c-kit ligand on the survival of various classes of human hematopoietic progenitor cells. Blood. 1994 Mar 15; 83(6):1507-14. PMID: 7510143.
      Citations: 10     Fields:    Translation:HumansCells
    236. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G, et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia. 1994 Mar; 8(3):465-75. PMID: 7907395.
      Citations: 13     Fields:    Translation:HumansCells
    237. Ray S, Ponnathpur V, Huang Y, Tang C, Mahoney ME, Ibrado AM, Bullock G, Bhalla K. 1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother Pharmacol. 1994; 34(5):365-71. PMID: 7915211.
      Citations: 6     Fields:    Translation:HumansCells
    238. Bullock G, Tang C, Tourkina E, Ibrado AM, Lutzky J, Huang Y, Mahoney ME, Bhalla K. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclo-phosphamide-induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp Hematol. 1993 Dec; 21(13):1640-7. PMID: 8243566.
      Citations: 5     Fields:    Translation:HumansCells
    239. Grant S, Baker M, Bhalla K. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report. Leukemia. 1993 Dec; 7(12):1933-8. PMID: 8255091.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    240. Bhalla K, Ibrado AM, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V, Mahoney ME. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1993 Nov 15; 82(10):3133-40. PMID: 8219202.
      Citations: 12     Fields:    Translation:HumansCells
    241. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 1993 Apr; 7(4):563-8. PMID: 8096557.
      Citations: 36     Fields:    Translation:HumansCells
    242. Bhalla K, Tourkina E, Huang Y, Tang C, Mahoney ME, Ibrado AM. Effect of hemopoietic growth factors G-CSF and pIXY 321 on the activity of high dose Ara-C in human myeloid leukemia cells. Leuk Lymphoma. 1993; 10 Suppl:123-31. PMID: 7683227.
      Citations: 1     Fields:    Translation:HumansCells
    243. Bhalla K, Tang C, Ibrado AM, Grant S, Tourkina E, Holladay C, Hughes M, Mahoney ME, Huang Y. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose Ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1992 Dec 01; 80(11):2883-90. PMID: 1450413.
      Citations: 8     Fields:    Translation:HumansCells
    244. Bhalla K, Bullock G, Lutzky J, Holladay C, Ibrado AM, Jasiok M, Singh S. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells. Leukemia. 1992 Aug; 6(8):814-9. PMID: 1640734.
      Citations: 2     Fields:    Translation:HumansCells
    245. Grant S, Traylor R, Bhalla K, McCrady C, Pettit GR. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells. Leukemia. 1992 May; 6(5):432-9. PMID: 1593908.
      Citations: 2     Fields:    Translation:HumansCells
    246. Bhalla K, Holladay C, Lutzky J, Ibrado AM, Bullock G, Jasiok M, Singh S. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. Gynecol Oncol. 1992 Apr; 45(1):32-9. PMID: 1601333.
      Citations: 1     Fields:    Translation:HumansCells
    247. Bhalla K, Swerdlow P, Grant S. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells. Blood. 1991 Dec 01; 78(11):2937-44. PMID: 1954383.
      Citations: 7     Fields:    Translation:HumansCells
    248. Bhalla K, Birkhofer M, Bhalla M, Lutzky J, Hindenburg A, Cole J, Ince C. A phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer. Am J Clin Oncol. 1991 Dec; 14(6):509-13. PMID: 1957839.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    249. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood. 1991 Nov 15; 78(10):2674-9. PMID: 1824260.
      Citations: 3     Fields:    Translation:HumansCells
    250. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Safah H, Graham G. Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells. Exp Hematol. 1991 Aug; 19(7):669-73. PMID: 1893953.
      Citations: 2     Fields:    Translation:Humans
    251. Grant S, Bhalla K, McCrady C. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells. Leuk Res. 1991; 15(4):205-13. PMID: 2030601.
      Citations: 3     Fields:    Translation:HumansCells
    252. Grant S, Bhalla K, Arlin Z, Howe CW. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture. Exp Hematol. 1990 Jan; 18(1):41-8. PMID: 2298268.
      Citations: 3     Fields:    Translation:HumansCells
    253. Bhalla K, Birkhofer M, Li GR, Grant S, MacLaughlin W, Cole J, Graham G, Volsky DJ. 2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity. Blood. 1989 Nov 01; 74(6):1923-8. PMID: 2572282.
      Citations: 5     Fields:    Translation:HumansCells
    254. Hindenburg AA, Gervasoni JE, Krishna S, Stewart VJ, Rosado M, Lutzky J, Bhalla K, Baker MA, Taub RN. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res. 1989 Aug 15; 49(16):4607-14. PMID: 2545346.
      Citations: 31     Fields:    Translation:Cells
    255. Lutzky J, Astor MB, Taub RN, Baker MA, Bhalla K, Gervasoni JE, Rosado M, Stewart V, Krishna S, Hindenburg AA. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res. 1989 Aug 01; 49(15):4120-5. PMID: 2568167.
      Citations: 19     Fields:    Translation:HumansCells
    256. Bhalla K, Birkhofer M, Grant S, Graham G. The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells. Exp Hematol. 1989 Jan; 17(1):17-20. PMID: 2783247.
      Citations: 11     Fields:    Translation:HumansCells
    257. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia. 1988 Dec; 2(12):810-3. PMID: 3264363.
      Citations: 3     Fields:    Translation:HumansCells
    258. Bhalla K, Birkhofer M, Grant S, Baker M, MacLaughlin W, Cole J, Graham G. Phase I clinical and pharmacologic study of deoxycytidine. Leukemia. 1988 Oct; 2(10):709-10. PMID: 3172847.
      Citations:    Fields:    Translation:Humans
    259. Bhalla K, Cole J, MacLaughlin W, Arlin Z, Baker M, Graham G, Grant S. Effect of deoxycytidine on the metabolism and cytotoxicity of 5-aza-2'-deoxycytidine and arabinosyl 5-azacytosine in normal and leukemic human myeloid progenitor cells. Leukemia. 1987 Dec; 1(12):814-9. PMID: 2447450.
      Citations: 1     Fields:    Translation:HumansCells
    260. Bhalla K, MacLaughlin W, Cole J, Arlin Z, Baker M, Graham G, Grant S. Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity. Blood. 1987 Aug; 70(2):568-71. PMID: 3607288.
      Citations: 6     Fields:    Translation:HumansCells
    261. Bhalla K, Grant S. Effect of deoxycytidine on the in vitro response of human leukemia cells to inhibitors of de novo pyrimidine biosynthesis. Cancer Chemother Pharmacol. 1987; 19(3):226-32. PMID: 3581416.
      Citations: 1     Fields:    Translation:HumansCells
    262. Bhalla K, Cole J, MacLaughlin W, Baker M, Arlin Z, Graham G, Grant S. Deoxycytidine stimulates the in vitro growth of normal CFU-GM and reverses the negative regulatory effects of acidic isoferritin and prostaglandin E1. Blood. 1986 Nov; 68(5):1136-41. PMID: 3464321.
      Citations: 1     Fields:    Translation:HumansCells
    263. Grant S, Bhalla K, Gleyzer M. Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells. Leuk Res. 1986; 10(9):1139-46. PMID: 2429121.
      Citations: 5     Fields:    Translation:HumansCells
    264. Bhalla K, Hindenburg A, Taub RN, Grant S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res. 1985 Aug; 45(8):3657-62. PMID: 3860286.
      Citations: 22     Fields:    Translation:HumansCells
    265. Grant S, Bhalla K, Weinstein B, Pestka S, Mileno MD, Fisher PB. Recombinant human interferon sensitizes resistant myeloid leukemic cells to induction of terminal differentiation. Biochem Biophys Res Commun. 1985 Jul 16; 130(1):379-88. PMID: 3861180.
      Citations: 5     Fields:    Translation:HumansCells
    266. Grant S, Bhalla K, Gleyzer M. Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis. Cancer Res. 1984 Dec; 44(12 Pt 1):5505-10. PMID: 6208998.
      Citations: 9     Fields:    Translation:HumansCells
    267. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Cancer Res. 1984 Nov; 44(11):5029-37. PMID: 6091869.
      Citations: 22     Fields:    Translation:HumansCells
    268. Bhalla K, Nayak R, Deitch A, Grant S. Synergistic interaction between acivicin (AT-125) and 6-thioguanine in the murine leukemia L1210. Biochemical and cytokinetic considerations. Biochem Pharmacol. 1984 Jan 15; 33(2):247-54. PMID: 6200115.
      Citations:    Fields:    Translation:Animals
    269. Grant S, Bhalla K, Rauscher F, Cadman E. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60. Cancer Res. 1983 Nov; 43(11):5093-100. PMID: 6577943.
      Citations: 1     Fields:    Translation:HumansCells
    270. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. Journal of Clinical Investigation. 120:4569-4582.
    271. Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic myeloid progenitor cells.
    272. Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML. Cancer Biology and Therapy. 5:711.
    273. Importance of rational pre-clinical development. Cancer Biology and Therapy. 4.
    274. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clinical Lymphoma, Myeloma and Leukemia.
    275. Nucleophosmin (Npm1). 251-273.
    276. Differential effect of deoxycytidine on pyrimidine antagonist mediated growth suppression in normal versus leukemic human myeloid progenitor cells.
    277. Non-small-cell lung cancer adjuvant therapy. Oncology (Switzerland). 21:179-182.
    278. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia. 30:504-508.
    279. Antitumor synergism between acivicin (AT-125) and 6-thioguanine in the murine leukemia L1210. Clinical Research. 30.
    280. NEDD8 and HDACs. Blood. 127:2168-2170.
    281. Overexpression of Bcl-xL inhibits ARA-C-induced mitochondrial perturbations that activate the molecular cascade of apoptosis. Experimental Hematology. 25:783.
    282. Erratum. Nature Immunology. 10:665.
    283. Potentiation of 6-thioguanine intracellular accumulation and cytotoxicity by methotrexate in L1210 cells.
    284. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia.
    285. Preferential enhancement of ara-C cytotoxicity by 2,3-dihydro-1H-imidazo [1,2-b] pyrazole (IMPY) in leukemic vs normal human myeloid progenitor cells.
    286. SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress-inducing agents. Cancer Research. 76:5467-5478.
    BHALLA's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (930)
    Co-Authors (92)
    Similar People (60)
    Same Department Expand Description